(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 July 2017 (27.07.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/127729 A1

(51) **International Patent Classification**:
C12N 5/0783 (2010.01) *A61K 35/17* (2014.01)

(21) **International Application Number**:
PCT/US2017/014408

(22) **International Filing Date**:
20 January 2017 (20.01.2017)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
62/281,064 20 January 2016 (20.01.2016) US
62/336,339 13 May 2016 (13.05.2016) US

(71) **Applicant**: **FATE THERAPEUTICS, INC.** [US/US]; 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US).

(72) **Inventors**: **ROSEN, Jonathan**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **REZNER, Betsy**; c/o Fate Therapeutics, Inc, 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **VALAMEHR, Bahram**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **BJORDAHL, Ryan**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US). **PERALTA, Eigen**; c/o Fate Therapeutics, Inc., 3535 General Atomics Court, Suite 200, San Diego, California 92121 (US).

(74) **Agents**: **NGUYEN, Thu** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) **Title**: COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES




Figure 1

(57) **Abstract**: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

WO 2017/127729 A1

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*